Kelley Dougherty - United States | Professional Profile | LinkedIn
Teva Is at Center of Drug Price-Fixing Case Filed by States - Bloomberg
Teva resuelve demanda de accionistas por precio de medicamentos genéricos - enFarma
Kelley Dougherty - Underwriting assistant for-Jumbo Non Delegated - Guaranteed Rate | LinkedIn
Escasea el Adderall, un medicamento para el TDAH - Consumer Health News | HealthDay
Teva orchestrated a massive price fixing scheme with generic competitors, states allege
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
Teva Announces Appointment of New Global R&D and Chief Medical Officer | Business Wire
Teva Pharmaceuticals at heart of major price fixing suit in US - www.israelhayom.com
Teva among generic drugmakers hoping to settle US antitrust probe - PMLiVE
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
/cloudfront-us-east-2.images.arcpublishing.com/reuters/UBZLT4WEPVJY3CYNX7QVXH3BZU.jpg "Teva delayed generic EpiPen, Nuvigil in illegal scheme, new suit says | Reuters")
Teva delayed generic EpiPen, Nuvigil in illegal scheme, new suit says | Reuters
Teva Wins Patent Case Related to Orexo Opioid-Treatment Drug - Bloomberg
Teva Launches New “Pivot to Growth” Strategy
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva reaches $925K settlement with Mississippi in price-fixing case—and it hopes other states will follow suit | Fierce Pharma
Kelley Dougherty - United States | Professional Profile | LinkedIn
Teva Canada Charts a New Prescription for Care
Kelley Dougherty - United States | Professional Profile | LinkedIn
States reach deal over marketing, safety of generic opioids - WHYY
Teva Announces Appointment of New Global R&D and Chief Medical Officer
Kelley Dougherty - United States | Professional Profile | LinkedIn
Kelley Dougherty - Head of Corporate Affairs — Teva Pharmaceuticals, North America - Teva Pharmaceuticals | LinkedIn
Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook
